Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 9, Issue 3, Pages 429-439
Publisher
Informa UK Limited
Online
2015-12-18
DOI
10.1586/17512433.2016.1133288
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
- (2015) J. P. Gisbert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
- (2015) Mahmoud H Mosli et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Management of IBD Patients with Current Immunosuppressive Therapy and Concurrent Infections
- (2015) Jean-Fran�ois Rahier DIGESTIVE DISEASES
- Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab
- (2015) Casper Steenholdt et al. DIGESTIVE DISEASES AND SCIENCES
- Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy
- (2015) Cédric Duron et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
- (2015) Paolo Biancheri et al. GASTROENTEROLOGY
- Immunogenicity to infliximab is associated with HLA-DRB1
- (2015) Thomas Billiet et al. GUT
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- Infliximab-Related Infusion Reactions: Systematic Review
- (2015) Lev Lichtenstein et al. Journal of Crohns & Colitis
- Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
- (2015) X. Roblin et al. Journal of Crohns & Colitis
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- (2015) Reena Khanna et al. LANCET
- Disease monitoring in inflammatory bowel disease
- (2015) Shannon Chang WORLD JOURNAL OF GASTROENTEROLOGY
- Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs
- (2015) Kristian Thorlund et al. Expert Review of Gastroenterology & Hepatology
- Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease
- (2015) Brian Bressler et al. Canadian Journal of Gastroenterology and Hepatology
- Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
- (2014) Diane R. Mould et al. AAPS Journal
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Influence of Combination Therapy with Immune Modulators on Anti-TNF Trough Levels and Antibodies in Patients with IBD
- (2014) Tamara van Schaik et al. INFLAMMATORY BOWEL DISEASES
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
- (2014) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
- (2014) Madeline Therese Frederiksen et al. INFLAMMATORY BOWEL DISEASES
- Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: Changes following treatment with immunomodulators and/or anti-TNF antibodies
- (2014) Nadia Moreno et al. Journal of Crohns & Colitis
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases
- (2013) Anthony Lopez et al. INFLAMMATORY BOWEL DISEASES
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
- (2013) Martine De Vos et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease
- (2013) Sorcha O’Meara et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method
- (2012) Liselotte Coorevits et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response
- (2012) Lior Katz et al. INFLAMMATORY BOWEL DISEASES
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
- (2012) Ren Mao et al. INFLAMMATORY BOWEL DISEASES
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
- (2012) Geert DʼHaens et al. INFLAMMATORY BOWEL DISEASES
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
- (2012) Axel Dignass et al. Journal of Crohns & Colitis
- Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis
- (2012) Shota Saito et al. Journal of Crohns & Colitis
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
- (2012) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
- (2011) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
- (2011) Edouard Louis et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity
- (2011) Z.H. Xu et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach
- (2010) Margarita Elkjaer et al. GUT
- Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers
- (2010) S. Travis et al. GUT
- Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience
- (2010) Vincent Billioud et al. INFLAMMATORY BOWEL DISEASES
- Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis
- (2010) Chuanpu Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
- (2010) Gert Van Assche et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients
- (2009) Sunanda V. Kane et al. ADVANCES IN THERAPY
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
- (2009) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
- (2009) Fabian Schnitzler et al. INFLAMMATORY BOWEL DISEASES
- Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
- (2009) Zhenhua Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
- (2009) Laurent Beaugerie et al. LANCET
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical pharmacology and pharmacogenetics of thiopurines
- (2008) Srikumar Sahasranaman et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
- (2008) Brian G. Feagan et al. GASTROENTEROLOGY
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started